SCHEMBL496253

SCHEMBL496253

N#Cc1ccc(Cl)cc1N[C@H]1CCCC[C@@H]1NC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.40
CYP2C19 P33261 1/20 0.39
NOS2 P35228 1/20 0.39
PPARG P37231 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
RAB9A P51151 2/20 0.38
FER P16591 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4367918 1.00 ALDH1A1 (0.42) ALDH1A1LMNAMEN1HTTKMT2A
SCHEMBL4368419 0.85 FER (0.36) MEN1KMT2ATAS1R3TAS1R2FER
SCHEMBL496194 0.81 CHEK1 (0.40) ALDH1A1HTTATMNPSR1TAS1R3
SCHEMBL496442 0.81 FER (0.34) MEN1KMT2AFERL3MBTL1
SCHEMBL2709835 0.79 IRAK4 (0.39) ALDH1A1LMNAMEN1HTTKMT2A
SCHEMBL496451 0.79 IRAK4 (0.39) ALDH1A1LMNAMEN1HTTKMT2A
SCHEMBL496465 0.78 MEN1 (0.41) ALDH1A1LMNAMEN1HTTKMT2A
SCHEMBL495888 0.78 MEN1 (0.41) ALDH1A1LMNAMEN1HTTKMT2A
SCHEMBL9102105 0.78 GPR65 (0.40) FERDGAT1KCNH2ABL1
SCHEMBL2716165 0.78 GPR65 (0.40) FERDGAT1KCNH2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 ALDH1A1 1210/4885LMNA 3329/4885MEN1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.